Method for stimulating spinal cord regeneration with genetically modified human umbilical cord blood cells

FIELD: medicine.

SUBSTANCE: what is presented is a method for stimulating the post-traumatic spinal cord regeneration consisting in a single-stage transplantation of human umbilical cord blood mononuclear cells pre-transduced with recombinant adenovirus with a cloned gene of glial derived neurotrophic factor (gdnf), in the damage area.

EFFECT: using the invention enables providing a better outcome of the post-traumatic spinal cord regeneration, reduced length of staying in hospital of patients suffering from a spinal cord injury and improving the patients' quality of life.

1 ex

 

The invention relates to medicine, in particular to methods of treatment of spinal cord injuries using the introduction in the area of corruption genetically modified mononuclear blood cells of the human umbilical cord, and can be used in neurosurgery and traumatology.

Methods of treatment of the consequences of multiple trauma remain ineffective due to low regeneration potential in the brain. Enhancing the effectiveness of treatment for this disease is associated with gene-cell therapy. Cell transplantation in experimental spinal cord injury slightly stimulates regeneration and provides partial recovery of lost functions. Enhancement of therapeutic effect of transplantation of cells reached by genetic modification using non-viral and viral vectors. Transplantation of these cells provides long-lasting overexpression of key molecules that support the survival and differentiation of neural cells. In experimental spinal cord injury shown that transplantation of genetically modified cells using viral and plasmid vectors with cloned genes neurotrophic factors, protivopolozhnyh molecules, adhesion molecules and other stimulant neuroregenerative, is more effective than transplantat the I same native cells.

For delivery in the area of traumatic spinal cord injury therapeutic genes used differentiated, stem, induced pluripotent stem and progenitor cells. Quite promising are the blood cells of the umbilical cord, because of their low immunogenicity, availability, simplicity and security to obtain, the ability to withstand long-term storage. These cells have been intensively investigating for transplantation with brain injury (Cao, F. J., S. Q. Feng. "Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury." ChinMed J (Engl) 122(2). - 2009. - P.225-231; Schira, J., M. Gasis, et al. "Significant clinical, neuropathological and behavioural recovery from acute spinal cord trauma by transplantation of a well-defined somatic stem cell from human umbilical cord blood." Brain 135(Pt 2). - 2012. - P.431-446). The gene delivery using viral vectors in different experimental models of neurodegenerative diseases have shown improvement in function, that allows to consider this method as the most promising for targeted therapies in the pathology of the Central nervous system.

Member of the family of transforming growth factor beta (TGFβ) glial-derived neurotrophic factor (eng. glial cell line-derived neurotrophic factor, GDNF) is a potent factor in maintaining the viability of many populations of neurons, including motoneurons. That is why this neurotrophic factor associated with the future treatment of neurological R is straist.

In experimental spinal cord injury introduction in the area of corruption GDNF exerts a neuroprotective effect, supports the expression of proteins neurofilament, peptide associated with calcitonin genome (CGRP) and is associated with axonal protein 43 (GAP-43) (Cheng, N., J. P. Wu, et al. "Neuroprotection of glial cell line-derived neurotrophic factor in damaged spinal cords following contusive injury." J Neurosci Res 69(3). - 2002. - P.397-405). In combination with transplantation of Schwann cells GDNF inhibits the production of astrocytes molecules inhibitors of axon growth, which reduces the inhibitory effects of glial scar regeneration of nerve fibers (Deng, L.-X., J. Ni, et al. "GDNF modifies reactive astrogliosis allowing robust axonal regeneration through Schwann cell-seeded guidance channels after spinal cord injury." Experimental neurology 229(2). - 2011. - P.238-250). Many molecules produced GFAP-immunopositive astrocytes exert a neurotrophic effect, and the astrocytes form a potential space for the growth of axons. The results formed the basis for the concept of supporting axonal phenotype GFAP-immunopositive of astrocytes (growth-supportive phenotype) (White, R. E., M. Rao, et al. (2011). "Transforming growth factor alpha transforms astrocytes to a growth-supportive phenotype after spinal cord injury." JNeurosci 31(42): 15173-15187). GDNF has a direct stimulating effect on the growth of axons in the injured spinal cord stimulates their myelination, reduces apoptosis and degeneration of tissue (Iannotti, S., N. Li, et a. "Glial cell line-derived neurotrophic factor-enriched bridging transplants promote propriospinal axonal regeneration and enhance myelination after spinal cord injury." Exp Neurol 183(2). 2003. - P.379-393). In experimental spinal cord injury not only local but also systemic administration of GDNF inhibits the development of pathological manifestations (Kao, C.-N., S.-H. Chen, et al. "Exogenous administration of glial cell line-derived neurotrophic factor improves recovery after spinal cord injury." Resuscitation 77(3). - 2008. - P.395-400). While GDNF increases the number and caliber of regenerating axons, and stimulates the growth of axons in culture neurons in spinal ganglia (Zhang, L., Z. Ma, et al. "GDNF-enhanced axonal regeneration and myelination following spinal cord injury is mediated by primary effects on neurons." Glia 57(11). - 2009. - P.1178-1191).

There is a method of stimulating post-traumatic regeneration of the spinal cord by delivery to the site of injury is not neurotropism factor, and its gene. In the experiment with spinal cord injury have been shown to improve functional and structural indicators for local delivery of a gdnf gene in the composition of the plasmid vector using cationic liposomes (Lu, K. W., Z. Y. Chen, et al. "Protective effect of liposome-mediated glial cell line-derived neurotrophic factor gene transfer in vivo on motoneurons following spinal cord injury in rats." Chin J Traumatol 7(5). - 2004. - P.275-279), nanoparticles biorastvorimym polymer (Wang, Y.-C., Y.-T. Wu, et al. "Sustained intraspinal delivery of neurotrophic factor encapsulated in biodegradable nanoparticles following contusive spinal cord injury." Biomaterials 29(34). - 2008. - P.4546-4553) or in complex with what ntially against receptors for neurotrophic factors (Barati, S., P. R. Hurtado, et al. "GDNF gene delivery via the p75(NTR) receptor rescues injured motor neurons." Exp Neurol 202(1). - 2006. - P.179-188). Compared to non-viral vectors viral vectors are more transfectional activity. Injection in the area of traumatic injury of the spinal cord genetic constructions on the basis of herpes simplex virus gene gdnf improves recovery of function (Natsume, A., D. Wolfe, et al. "Enhanced functional recovery after proximal nerve root injury by vector-mediated gene transfer." Exp Neurol 184(2). - 2003. - P.878-886). Local delivery in the area of spinal cord injury of the same gene using adenoviral vector prevents retrograde atrophy corticospinal of motoneurons and promotes recovery of motor functions (Tang, X.-Q., Y. Wang, et al. "Adenovirus-mediated delivery of GDNF ameliorates corticospinal neuronal atrophy and motor function deficits in rats with spinal cord injury." Neuroreport 15(3). - 2004. - P.425-429). Injection of the transgene allows transliterate cells, the localization of which is limited to a fairly narrow area of introduction. However, when spinal cord injury in the pathological process involves an extensive area, adjacent to the epicenter of injury. So for the most complete manifestation of therapeutic effects of the introduced gene is necessary to ensure his presence not only in the midst of traumatic injury, but also in adjacent areas, as a rule, quite remote from this zone. To solve this problem, n is the most promising approach is the delivery of therapeutic genes at the cellular carriers. Numerous experimental studies have established that transplantation of transfected cells carrying the transgene, has a stimulating effect on post-traumatic spinal cord regeneration. Delivery of gdnf gene using transduced by retrovirus fibroblasts in the area of complete transection or dorsal hemisection spinal cord of rats was carried out in rats (Blesch, A., M. N. Tuszynski. "Cellular GDNF delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transections and dosage remyelination." J Comp Neurol 467(3). - 2003. - P.403-417), which failed to reveal signs of regeneration of nerve fibers and their remyelinization. However, fiber is not germinated after the injury area, and was not restored ties with target cells that had not led to an improvement in motor or sensory function. Cell-mediated delivery of gdnf gene carried out in the area of complete transection of the spinal cord of the rat thoracic by transplantation of transfected glial cells of the olfactory structures (Yan, N. C., Z. M. Zhang, et al. "The repair of acute spinal cord injury in rats by humans ensheathing cells graft modified by glia cell line-derived neurotrophic factor gene in combination with the injection of monoclonal antibody IN-1." Zhonghua Wai Ke Za Zhi 47(23). - 2009. - P.1817-1820). When comparing groups of animals with transplantation of transfected and native cells, the authors were able to show a steady germination regenerating fiber is n through the region of the gap only in the first case, which was accompanied by improved recovery of motor function.

Cell transplantation umbilical cord blood of a person with spinal cord injury inhibits inflammatory response, has neurotrophic activity and stimulates neovascularization (Chen, C. T., N. N. Foo, et al. "Infusion of human umbilical cord blood cells ameliorates hind limb dysfunction in experimental spinal cord injury through anti-inflammatory, vasculogenic and neurotrophic mechanisms." Pediatr Neonatol 49(3). - 2008. - P.77-83), reduces the expression of proapoptotic genes and supports the survival of neurons (Dasari, V. R., K. K. Veeravalli, et al. "Neuronal apoptosis is inhibited by cord blood stem cells after spinal cord injury " J. Neurotrauma 26(11). - 2009. - P.2057-2069). Several experimental models have established that the blood cells of the umbilical cord, producing colony-stimulating factor 1, thrombopoietin and interleukin-11, have immunomodulatory effects (Suen, Y., S. M. Lee, et al. "Decreased macrophage colony-stimulating factor mRNA expression from activated cord versus adult mononuclear cells: altered posttranscriptional stability." Blood 84(12). - 1994. - P.4269-4277; Taguchi, A., T. Soma, et al. "Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model." J Clin Invest 114(3). - 2004. - P.330-338; Vendrame, M., J. Cassady, et al. "Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct dementia volume." Stroke 35(10). - 2004. - P.2390-2395). According to our records transplantation of these cells, transfected with a plasmid with the genes of neurotrophic factors in the injury of the spinal cord of the rat has a marked stimulating effect on near the regeneration (Shaymardanova GF, Muhamedshina YAO and others, "Effect of transplantation in the area of traumatic injury of the spinal cord of the rat mononuclear blood cells of the umbilical cord human, recombinant genes VEGF and FGF2." J.Morphology 142(4). - 2012. - R.31-36).

Closest to the claimed invention is a method of stimulating post-traumatic regeneration of the spinal cord, used in the study (Yan, N. C., Z. M. Zhang, et al. "The repair of acute spinal cord injury in rats by humans ensheathing cells graft modified by glia cell line-derived neurotrophic factor gene in combination with the injection of monoclonal antibody IN-1." Zhonghua Wai Ke Za Zhi 47(23). - 2009. - P.1817 - 1820), according to which isolated from the body glial cells of the olfactory structures were transfusional in vitro lentiviruses vector with the gene gdnf. These cells transplanted rats in the injury area immediately after complete transection of the spinal cord in the thoracic region. Using a behavioral test "BBB" shows a more pronounced recovery of motor function than in animals with the same injury, but without the introduction of cells and in animals with the same injury, but with the introduction of nitrostilbene the same cells. Applied research method cell-mediated delivery of gdnf gene has the following disadvantages:

• the method of delivery of gdnf gene using lentiviruses vector, compared to the other most studied viral vectors, such as simple virus is on herpes, adenovirus, adeno-associated virus, is the least safe from the point of view uncontrolled differentiation of the transplanted cells and oncogenic potential;

• applied as carriers of the transgene glial cells of the olfactory structures, as well as Schwann cells, are characterized by low migration potential, which limits the delivery of therapeutic gene in the target tissue located away from the epicenter of traumatic injury;

• glial cells of the olfactory structures, as well as Schwann cells, as compared to stem cells and early cells predecessors are characterized by poor survival, which reduces the duration of therapeutic action deliver genes with them.

The objective of the proposed method is the stimulation of post-traumatic regeneration of the spinal cord by transplantation into the damage in mononuclear blood cells of the human umbilical cord, transduced recombinant replication-defective adenovirus carrying the gene for glial-derived neurotrophic factor (gdnf), which will overcome the aforementioned disadvantages of the nearest analogue of the invention and to achieve new technical result, namely:

• to provide a more complete restoration of structures of the spinal cord responsible for the implementation of the motor and sensory functions;

• reduce length of stay of patients with spinal cord injury in the hospital and improve the quality of life of patients of this cohort.

The problem is solved by a method of stimulating post-traumatic regeneration of the spinal cord by means of a single transplant immediately after damage in mononuclear blood cells of the human umbilical cord, transduced with recombinant adenovirus with the cloned gene glial derived neurotrophic factor (gdnf).

Research on the effectiveness of gene-cell therapy in spinal cord brain transplantation into the damaged transduced with recombinant adenovirus mononuclear blood cells of the umbilical cord as carriers of therapeutic gene cloned glial derived neurotrophic factor (gdnf) is available to the applicant the information sources are not identified.

The essence of the claimed technical solution is to promote post-traumatic regeneration of the spinal cord by means of a single transplant to the area of damage in mononuclear blood cells of the umbilical cord of a person previously transduced with recombinant adenovirus with the cloned gene glial derived neurotrophic factor (gdnf).

The inventive method operates on the known sequence of stages. To create recombinant the adenovirus used expression plasmid vector pAd/CMV/V5-DEST (Invitrogen, Catalog #V493-20, USA), in which the cloned gene gdnf technology Gateway® (Invitrogen, USA) using a reaction LR recombination (reaction-based site-specific recombination system of phage λ). Thus obtained recombinant plasmid encoding adenovirus genome with the insertion of a gene gdnf (pAd-GDNF), allows to obtain a recombinant adenovirus containing the desired transgene. Using restriction enzyme Pad was obtained linear plasmid pAd-GDNF, which was transfusional cells SOME A (Invitrogen, Catalog #R705-07, USA) for the Assembly and replication of adenovirus. Splitting vector contributes to the interaction of the left and right inverted terminal repeats and the removal of bacterial sequences (namely, the plot of the beginning of the pUC replication and gene resistance to ampicillin). The Assembly and replication of recombinant adenovirus occurs in the cell line SOME A - immortalization line primary embryonic cells of human kidney transformed with DNA fragments of adenovirus serotype 5. Cell line contains stably integrated into the genome of the e1 gene, which expresses proteins E1 (EA and E1b), necessary for the preparation of recombinant adenovirus. After receiving the crude viral lysate to increase the virus titer was used to amplify adenovirus Ad5-GDNF cells SOME A. 2 days after which argenia in cell culture was observed cytopathic effect that indicates that cells produce viral particles. Umbilical cord blood were taken after obtaining informed consent of the pregnant woman and prenatal screening for contraindications to donation of blood. Mononuclear blood cells from human umbilical cord was obtained by the method of sedimentation in a density gradient ficoll (Hawley, Hawley et al. 2004). After separation of mononuclear cells from umbilical cord blood were sown in the amount of 2×107cells in 10 cm culture cups for suspension cells (Jet Biofil") in the environment of the Needle, the modified Dulbecco (DMEM) containing 10% serum fruits cows (FBS).

The cells were transducible by adding 100 μl of recombinant adenovirus Ad5-GDNF (8×108PFU/ml) in 10 cm culture Cup. After transduction, the cells were incubated overnight at 37°C in a humid atmosphere containing 5% CO2. The cells were concentrated by tsentrifugirovaniem and purified from the culture medium by washing in a solution of Dulbecco (DPBS) without ions of CA2+and Mg2+. The washed cells were resuspendable in DPBS and the camera Goryaeva estimated their number and viability after coloring Trifanova blue. Further genetically modified cells are used for transplantation into the damaged rats with contusion model of spinal cord injuries.

The claimed method of stimulating Regener the tion of the spinal cord by transplantation of transduced with recombinant adenovirus with gdnf gene in mononuclear blood cells of human umbilical cord has been studied in laboratory rats and described in detail in the following examples.

The experiments were carried out on white rats-males weighing 150-200 g in accordance with the requirements of the local ethics Committee of the GOU VPO "Kazan state medical University". Animals were kept in plastic cages at a temperature of 18-20°C with free access to food and water. Surgical procedures rats were performed after narkotizirovannyh by intraperitoneal injection of chloral hydrate (Sigma) (80 mg/ml, 0.4 ml per 100 g).

Model dosed contusion injury of the spinal cord of the rat studied the effect on neuroregeneration transplantation in the area of damage in mononuclear blood cells of the human umbilical cord, transduced with recombinant adenovirus gene glial derived neurotrophic factor (gdnf). Rats under anesthesia at the level of the eighth segment of the spinal cord after laminectomy inflicted dosed contusion injury vertically falling metal rod weighing 10 g from a height of 25 mm Immediately after sewing injury in two points at a distance of 1 mm rostralnie and Caudalie from the epicenter of the injury and 0.5 mm lies lateral to the midline using a Hamiltonian of the syringe were injected with previously transduced with recombinant adenovirus gene gdnf mononuclear blood cells from human umbilical cord 1 million cells in 5 μl of DPBS (phosphate-saline buffer Dulbecco, sterile, the ez ions of CA 2+and Mg2+Biolot, Russia) in each point. Animals of the control group in the same experimental conditions, was introduced the same cells, transfetsirovannyh adenoviral vector with the gene of green fluorescent protein (egfp).

To evaluate the efficiency of recovery of motor function used behavioral test in the open field BBB (Basso, D. M., M. S. Beattie, J. C. Bresnahan. "A sensitive and reliable locomotor rating scale for open field testing in rats." Journal ofNeurotrauma 12. - 1995. - P.1-21).

Ha 30 days after application contusion injury were isolated spinal cord. On cryostatic transverse sections of the spinal cord at a distance of 1.5 cm from the epicenter of the injury carried out immunofluorescence reaction. To identify the antigen, the sections were incubated with primary antibodies against glial fibrillar acidic protein (GFAP, Santa Cruz, 1:200) overnight at 4°C, washed in phosphate-buffered saline and then incubated with secondary antibodies conjugated with fluorescent dye anti-mouse Alexa 647 (Invitrogen, 1:200) for 2 hours at room temperature. To visualize the nuclei of cells, the sections were additionally stained for 10 minutes at room temperature, 4',6-diamidino-2-phenylindole (DAPI, 10 μg/ml in phosphate buffer, Sigma). Stained sections were made in an environment that supports the fluorescence, and studied using confocal scanning microscope LSM 510Meta (Carl Zeiss).

1. Testing motor function using behavioral test "BBB"

The rate of recovery of motor function (BBB) for transplantation into the damaged spinal cord mononuclear blood cells of the human umbilical cord, transduced with recombinant adenoviruses with therapeutic gene gdnf increases by 58% (P<0.05) in comparison with the corresponding figure in animals of the control group with the introduction of the same cells transfected with the gene for green fluorescent protein (egfp). On term of 9, 11 and 13 days the indicator BBB in the experimental group compared with the control, respectively is increased by 62.7 percent, 59.5 per cent and 53.5 per cent.

2. Immunohistochemistry of spinal cord

To 30 days after contusion injury of the spinal cord of the rat and the introduction into the area of damage in mononuclear blood cells of the human umbilical cord, transduced with recombinant adenovirus genes with gdnf (experimental group) and egfp (control group), in white and gray matter of the detected GFAP+-cells. In the experimental group in the white matter (ventro-medial part of the anterior cord and the lateral part of the lateral cord) at a distance of 0.5 cm from the epicenter of the injury in a caudal direction population of GFAP+cells in 2 times higher than in the control group.

Thus, the results show is about that the inventive method for local delivery of a therapeutic gene glial derived neurotrophic factor (gdnf) into the injury of the spinal cord allows you to effectively stimulate post-traumatic spinal cord regeneration, which is manifested in the form of improvements to restore function and increase the number of reactive astrocytes, essential to the process of neurodegeneration. Revealed as a result of carrying out gene-cell therapy, the increase in the number of GFAP+-astrocytes should be considered as a positive factor encouraging neuroregenerative. This conclusion is based on the well-known view on the role of reactive astrocytes, which have antioxidant and cytoprotective action on neurons and melanoblastoma oligodendrocytes, including by increasing the expression of membrane Transporter of glutamate and reduction of the content of this excitatory neurotransmitter in the extracellular space (Lepore, A., J. O'donnell, et al. "Reduction in expression of the astrocyte glutamate transporter, GLT1, worsens functional and histological outcomes following traumatic spinal cord injury." Glia. -2011).

The applicant for the first time:

- applied method for local delivery in the area of traumatic spinal cord injury therapeutic gene glial derived neurotrophic factor (gdnf) by mononuclear blood cells of the umbilical cord che is oweka, translotsirovannoi recombinant adenovirus with these cloned genome;

- shows the stimulating effect of gene-cell therapy that combines the delivery in the area of damage in mononuclear blood cells of human umbilical cord that has its own therapeutic effect, and the cloned gene gdnf on posttraumatic restoration of the structure and function of the spinal cord.

Using the proposed method of stimulating post-traumatic regeneration of the spinal cord by the method of transplantation of mononuclear blood cells of the human umbilical cord, transduced with recombinant adenovirus with the cloned gene glial derived neurotrophic factor (gdnf), allows you to:

to improve the results of post-traumatic regeneration of the spinal cord in the form of a more complete recovery of the structure and functions of the authority;

- reduce the time of stay of patients with spinal cord injury in the hospital and improve the quality of life of patients of this cohort.

The way to promote post-traumatic regeneration of the spinal cord, which consists in a single transplant to the area of damage in mononuclear blood cells of the umbilical cord of a person previously transduced with recombinant adenovirus with the cloned gene glial derived neurotrophic factor (gdnf).



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, particularly to a pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues, and to using it. The pharmaceutical composition for dehydration, atrophy and removal of abnormal tissues contains a composite of an inorganic polymer iron salt as an active ingredient; the composite of the inorganic polymer iron salt is polymer ferrous sulphate silicate (PFSS), or polyferrous silicate chloride (PFSC), or polyphosphate ferrous sulphate (PPFS). Using the pharmaceutical composition consists in preparing the drug for dehydration, atrophy and removal of abnormal tissues.

EFFECT: pharmaceutical composition is effective for dehydration, atrophy and removal of abnormal tissues in treating haemorrhoids, haemangiomas, varicose veins, burns, bleeding traumatic wounds, local wounds caused by chemicals or microorganisms.

9 cl, 12 dwg, 2 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and can be used for modification of eating behaviour in a subject. For this purpose peripheral introduction of PYY in an amount, efficient for achieving physiological levels of PYY3-36 in blood, plasma and serum, determined after food intake, is performed; or performed is peripheral introduction of PYY agonist in an amount, efficient for imitation of physiological levels of PYY3-36 in blood, plasma or serum, determined after food intake with modification of eating behaviour, by reducing intake of calories, food consumption or appetite reduction or increase of energy consumption in the subject. Also claimed is application of PYY or its agonist as an active ingredient in production of medication.

EFFECT: group of inventions provides weight reduction in the subject due to reduction of intake of calories, appetite reduction or increase of energy consumption in the subject.

50 cl, 9 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a preparation for involving a mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow, which is introduced into the blood vessel or muscle and which contains any of components: (a) protein HMGB1; (b) HMGB1 protein-secreting cell; (c) a vector, into which HMGB1 protein-coding DNA is inserted; (d) protein HMGB2; (e) HMGB2 protein-secreting cell; (f) a vector, into which HMGB2 protein-coding DNA is inserted; (g) protein HMGB3; (h) HMGB3 protein-secreting cell; and (i) a vector, into which HMGB3 protein-coding DNA is inserted.

EFFECT: elaboration of the preparation for involving the mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow.

3 cl, 6 ex, 1 tbl, 14 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely immunology, and may be used for reducing eosinophil count in a human body. That is ensured by the parenteral administration of approximately 0.01 mg/kg to approximately 0.25 mg/kg of a monoclonal chimeric humanised antibody or a human antibody which binds to IL-5P and contains an immunoglobulin Fc fragment and is fucose-free; the administered antibody reduces the peripheral blood circulating eosinophil count below the detection threshold, and the circulating eosinophil calculation level remains below the detection threshold for approximately 28 days after antibody dosing.

EFFECT: using the given method leads to fast and prolonged reduction of peripheral blood eosinophils.

9 cl, 14 ex, 31 dwg, 1 tbl

FIELD: chemistry, pharmacology.

SUBSTANCE: invention relates to field of pharmacology and medicine and deals with application of halogenides of 1,3-disubstituted 2-aminobenzimidazolium, of general formula I as inhibitors of Na+/H+-exchange, as well as novel 1,3-disubstituted halogenides of 2- aminobenzimidazolium.

EFFECT: increased efficiency of inhibitors.

3 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology and concerns an isolated polypeptide, a pharmaceutical composition containing such polypeptide, as well as a method of treating cancer. The presented polypeptide contains an amino acid sequence corresponding to SEQ. ID. NO: 2 or SEQ ID NO: 4. There are also characterised fragments or versions of the presented polypeptide.

EFFECT: group of inventions may be used to stimulate the immune system in treating malignant diseases and for diagnosing loss of immunologic activity.

7 cl, 7 dwg, 1 tbl, 6 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula R1 represents (1) hydrogen atom, (2) halogen atom, (3) C1-6alkyl group or (4) C1-6halogenalkyl group (whereR1 can be present in any substitutable position of benzene or pyridine ring); L represents (1) simple bond, (2) -O- or (3) -CH2O- (where L can be present in position 5 or 6 of condensed cycle); R2 represents (1) C6-10aryl group (C6-10aryl group is optionally condensed with C3-6cycloalkane), optionally substituted with substituent(s), X represents carbon atom or nitrogen atom. Other values of radicals are given in the invention formula.

EFFECT: obtaining compounds which can be used to prepare medication for treatment or prevention of such diseases as neuropathic pain, nociceptive pain, dysuria, disseminated sclerosis, etc.

19 cl, 47 tbl, 237 ex

FIELD: chemistry.

SUBSTANCE: invention relates to compound of formula , where Z stands for phenyl, substituted with 1-5 halogen atoms, selected from fluorine and chlorine; R4 stands for C1-C4-alkyl with linear chain or C3-C4-alkyl with branched chain; or to its pharmaceutically acceptable salt. Invention also relates to pharmaceutical composition, inhibiting prolyl hydroxylase activity, based on said compounds.

EFFECT: obtained are novel compounds and based on them pharmaceutical composition, which can be applied in medicine for treatment of diseases, associated with immune response of organism.

18 cl, 20 dwg, 8 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: blood is examined for angiogenic factors, namely soluble fms-like tyrosine kinase (sFlt-1) and placental growth factor (PIGF). An angiogenic factor (Ka) is calculated by formula: Ka=sFlt-1/PlGF×10. If Ka is 10 or less, the pregnant woman is stated to require no admission to hospital, no case follow-up; doctor's appointments are scheduled. If Ka falls within the range of 10 to 50, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed; an amniotic fluid index (AFI) is calculated; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 10 days. The amount of infusion makes 400 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control ultrasonography, Doppler monitoring, foetal monitoring, AFI and Ka measurements are performed 2 weeks later. The pregnant woman is discharged from hospital if observing no negative trends. If Ka falls within the range of 50 to 100, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days The amount of infusion makes 800 ml a day. The prescribed preparations are Actovegin, Trental, Instenon, Carnitini chloridum. Control Doppler monitoring and foetal monitoring are performed every 3 days; 2 weeks later control Ka is measured. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 100 or more, but less than 150, the pregnant woman is admitted to hospital, wherein foetal monitoring, Doppler monitoring are performed, and AFI is measured; a therapy aiming at the uterine-placental blood flow improvement is prescribed for 14 days. The amount of infusion makes not less than 800 ml a day with the same preparations prescribed. Those are added with the preparations for homeostasis correction, including Fraxiparine, Fragmin, Clexane optionally. Control Doppler monitoring and foetal monitoring are daily. Hypamnion also requires measuring control AFI. If a gestational age is less than 34 weeks, respiratory distress syndrome (RDS) should be prevented by administering the preparation Dexon 24 mg according to the schedule: 6 mg every 12 hours 4 times. Control Ka is necessarily measured after 2 weeks of the treatment. If the trend is positive, the pregnant woman may be discharged from hospital, while no positive trend requires another 2 weeks of the therapy. If Ka is 150 or more, and the gestational age is more than 34 weeks, the therapeutic approach is the same, as for Ka being within 100 to 150, control Doppler monitoring, foetal monitoring are performed twice a day, as well as measuring AFI. If observing no foetal weight gain for 2 weeks of the therapy or the functional state of the foetus deteriorates, a Cesarean section is performed. If the gestational age is 34-36 weeks, the therapeutic approach and follow-up are the same as for the gestational age of 34 weeks, except for the prevention of foetal RDS. However, if observing the deterioration of a foetal movement pattern or the functional status of the foetus, a Cesarean section is performed according to the foetal monitoring and Doppler monitoring findings. If the gestational age is more than 36 weeks, and Ka is 150 or more, pre-mature delivery is applied.

EFFECT: optimal selection of the therapeutic approach ensured by determining the values reflecting the severity of the cardiovascular disorder directly in the uterine-placental complex and mother's and foetus's compensatory capacities.

5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent for preventing chronic fatigue syndrome in males. The agent for preventing chronic fatigue syndrome in males is presented in the form of suppositories containing male red deer's blood plasma, dry sweetvetch extract, L-arginine and additives in certain proportions.

EFFECT: agent is effective to prevent chronic fatigue syndrome in males; it corrects the psychoemotional status, and also promotes the activation of testosterone synthesis.

FIELD: medicine.

SUBSTANCE: method involves using a photosensitiser (PS) pre-detected in the tumour by its fluorescence that is followed by tumour irradiation by light emission at a wave length in the spectral range of PS peak absorption. The PS is presented by the genetically coded protein KillerRed by providing its tumour expression by gene insertion into the tumour cells. The tumour is exposed to the light emission at energy density of 180-270 J/cm2 3 times every second day or 7 times daily. The protein KillerRed is preferentially localised either in mytochondria and nuclei, or in nuclei.

EFFECT: method provides high-selectivity PS effect on the tumour, reduced toxic load on the intact organs and tissues, the absence of PS redistribution in the tumour, with no need for the constant radiation control.

2 cl, 6 dwg, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a preparation for involving a mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow, which is introduced into the blood vessel or muscle and which contains any of components: (a) protein HMGB1; (b) HMGB1 protein-secreting cell; (c) a vector, into which HMGB1 protein-coding DNA is inserted; (d) protein HMGB2; (e) HMGB2 protein-secreting cell; (f) a vector, into which HMGB2 protein-coding DNA is inserted; (g) protein HMGB3; (h) HMGB3 protein-secreting cell; and (i) a vector, into which HMGB3 protein-coding DNA is inserted.

EFFECT: elaboration of the preparation for involving the mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow.

3 cl, 6 ex, 1 tbl, 14 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: presented group of inventions refers to medicine and veterinary science. What is presented is a biocomposite for performing reparative processes following an injury in a mammal, containing a carrier, at least one nucleic acid containing genes coding VEGF and/or SDF-1, and cells ensuring reparative regeneration. There are presented methods for preparing the above biocomposite and a kit for preparing the same. There are also presented a method for providing injury healing in a mammal and a method for delivering nucleic acid.

EFFECT: presented group of inventions provides effective tissue regeneration following the injury in the mammal by using the three-component biocomposite consisting of the carrier, at least one nucleic acid and the cells ensuring reparative regeneration.

16 cl, 4 dwg, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to biotechnology, more specifically to using microRNA (miRNA) for treating pathological cardiac hypertrophy, myocardial infarction or cardiac failure. The method provides introducing a first anti-sense oligonucleotide containing a sequence that is at least partially complementary to the mature nucleotide sequence miR-208a or miR-208b, and a second anti-sense oligonucleotide containing a sequence that is at least partially complementary to the mature nucleotide sequence miR-499 into an individual suffering the cardiac activity.

EFFECT: combined introduction of the above oligonucleotides ensured by manifesting the synergetic effect enables a more effective decrease of the expression or activity of miR-208a or miR-208b and miR-499 in individual's cardiac cells.

30 cl, 7 dwg, 5 ex

FIELD: biotechnologies.

SUBSTANCE: pox virus of variolovaccine is proposed, which includes a defect F2L gene and a suicide gene. Pox virus has oncolytic activity. Besides, a reproduction method of such pox virus and its use for treatment of proliferative diseases or diseases with increased activity of osteoclasts is proposed.

EFFECT: improving compound application efficiency.

31 cl, 12 dwg, 3 tbl

FIELD: biotechnologies.

SUBSTANCE: peptide of DGSVVVNKVSELPAGHGLNVNTLSYGDLAAD structure is used for suppression of allergic inflammation of respiratory passages, for prophylaxis and treatment of arthritis, as well as for pain relief. A peptide is effective as an adjuvant and for stimulation of IL-12 products in a cell.

EFFECT: peptide allows increasing IL-12 products by 10 times relative to normal levels of IL-12 cellular production.

19 cl, 25 dwg, 10 ex

FIELD: biotechnologies.

SUBSTANCE: poxvirus includes defective gene I4L and/or F4L and target nucleic acid containing suicide gene. Besides, a composition containing such a poxvirus, its use for obtaining medical preparation and a treatment method of proliferative disease or disease with increased activity of osteoclasts with its application are described. The proposed group of inventions can be used in medicine.

EFFECT: poxvirus of variolovaccine has oncolytic activity.

34 cl, 18 dwg, 5 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine and may be used for preventing and treating the diseases wherein endogenous production of cytokines and hemopoietins is advisable to be stimulated. What is presented is a method for stimulating endogenous production of cytokines and hemopoietins which is based on introducing a preparation presenting a double-stranded genomic sonicated human DNA of fragment size 200-6000 base pairs into the patient's body. The preparation is used in the tableted form in the number of 3 tablets containing 5 mg of the active substance of the preparation daily for 1-14 days.

EFFECT: invention provides more effective stimulation.

1 cl, 21 dwg

FIELD: biotechnologies.

SUBSTANCE: genetic structure pAd-SM is produced, being built by homological recombination of the vector pAdEasy-1, containing the main part of genome of adenovirus and plasmid pAdTrack-CMV, where cDNA fragments of human genes SOX2 and C-MYC are placed, being connected with a nucleotide sequence that codes P2A-peptide. The plasmid pAd-SM produced as a result of homological recombination contains a fragment SOX2-P2A-C-MYC under control of a constitutive promotor CMV.

EFFECT: possibility to produce adenovirus particles for simultaneois delivery of genes and expression of proteins SOX2 and C-MYC in human cells, pAd-SM contains a gene that codes a fluorescent protein EGFP, under control of a CMV promotor, which makes it possible to track transduction of cells and elimination of virus DNA from a cell.

3 cl, 1 dwg

FIELD: biotechnologies.

SUBSTANCE: plasmid genetic structure pOK-DsRed2 is produced, being built on the basis of a plasmid vector pIRES (Clontech), where fragments of cDNA of human genes OCT4 and KLF4 are placed, being connected with a nucleotide sequence coding P2A-peptide and gene cDNA, coding fluorescent protein DsRed2. Transcription of a single mRNA OCT4-F2A-KLF4-IRES-DsRed2 is carried out from constitutive promotor p CMV IE, providing for high level of mRNA lifelength.

EFFECT: availability of F2A and IRES sequences makes it possible to simultaneously translate proteins OCT4, KLF4 and DsRed2 from one mRNA molecule.

2 cl, 1 dwg, 1 tbl

FIELD: biotechnology, veterinary science.

SUBSTANCE: invention relates to therapeutic vector used in therapy of infectious diseases in cats that comprises at least one foreign nucleic acid each of that (a) encodes protein taken among the group consisting of feline protein CD28 represented in SEQ ID NO:8 or its immunogenic moiety; feline protein CD80 represented in SEQ ID NO:2 or 3, or its immunogenic moiety; feline protein CD86 represented in SEQ ID NO:6 or its immunogenic moiety, or feline protein CTLA-4 represented in SEQ ID NO:10 or its immunogenic moiety; and (b) nucleic acid that is able to be expressed in insertion of vector in the corresponding host. Indicated therapeutic vector is used in effective dose as component of vaccine against infectious diseases in cats for their immunization and in methods for enhancement or inhibition of immune response in cats and reducing or eradication of tumor in cats. Invention provides stimulating the activation and proliferation of T cells and to enhance effectiveness of control of infectious diseases in cats.

EFFECT: valuable biological properties of recombinant virus.

41 cl, 13 dwg

Up!